Last reviewed · How we verify

Oral antihyperglycemics — Competitive Intelligence Brief

Oral antihyperglycemics (Oral antihyperglycemics) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Oral antihyperglycemic agents (multiple classes). Area: Diabetes.

phase 3 Oral antihyperglycemic agents (multiple classes) Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

Oral antihyperglycemics (Oral antihyperglycemics) — Eli Lilly and Company. Oral antihyperglycemics lower blood glucose levels through various mechanisms including insulin secretion enhancement, insulin sensitivity improvement, or glucose absorption reduction.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Oral antihyperglycemics TARGET Oral antihyperglycemics Eli Lilly and Company phase 3 Oral antihyperglycemic agents (multiple classes)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Oral antihyperglycemic agents (multiple classes) class)

  1. Eli Lilly and Company · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Oral antihyperglycemics — Competitive Intelligence Brief. https://druglandscape.com/ci/oral-antihyperglycemics. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: